<DOC>
	<DOCNO>NCT00006388</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . Drugs tamoxifen may make tumor cell sensitive radiation therapy . PURPOSE : Phase II trial study effectiveness combine radiation therapy tamoxifen treat patient newly diagnose supratentorial glioblastoma multiforme .</brief_summary>
	<brief_title>Radiation Therapy Tamoxifen Treating Adults With Newly Diagnosed Supratentorial Glioblastoma Multiforme</brief_title>
	<detailed_description>OBJECTIVES : I . Determine whether high-dose tamoxifen initiate begin conventional radiotherapy improve median survival time adult newly diagnose , supratentorial glioblastoma multiforme . II . Determine feasibility toxicity high-dose tamoxifen patient . III . Determine overall survival respect protein kinase C lab correlate patient treated regimen . OUTLINE : This multicenter study . Beginning within 5 week surgery , patient undergo radiotherapy brain 5 day week 6 week . Patients receive high-dose oral tamoxifen every 6 hour begin day 1 radiotherapy continue absence disease progression . Patients follow every 3 month year 1 , every 4 month 1 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 72 patient accrue study within 6 month .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove newly diagnose , supratentorial glioblastoma multiforme ( area necrosis ) Diagnosis must make surgical biopsy excision within past 5 week No recurrent malignant glioma No metastases tentorium beyond cranial vault PATIENT CHARACTERISTICS : Age : Adult Performance status : Karnofsky 70100 % OR Zubrod 01 Life expectancy : At least 8 week Hematopoietic : Hemoglobin least 10 g/dL ( transfusion allow ) Hematocrit least 30 % ( transfusion allow ) Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 2.0 mg/dL serum glutamate pyruvate transaminase ( SGPT ) serum glutamate oxaloacetate transaminase ( SGOT ) great 2 time normal Renal : Blood urea nitrogen great 25 mg/dL Creatinine great 1.5 mg/dL Cardiovascular : No active thrombophlebitis Other : Recovered postoperative infection complication No major medical illness psychiatric impairment would preclude study participation No active connective tissue disorder , lupus scleroderma No malignancy within past 5 year except nonmelanomatous skin cancer carcinoma situ cervix bladder No prior endometrial cancer atypical endometrial hyperplasia No AIDS Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : At least 12 month since prior tamoxifen Radiotherapy : See Disease Characteristics No prior radiotherapy head neck Surgery : See Disease Characteristics Recovered prior surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>